Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells

Figure 5 The effect of upregulation or downregulation of miR-29b-3p on high glucose and free fatty acid-induced ferroptosis of endothelial cells. A-C: Relative expression of miR-29b-3p in cardiomyocytes, endothelial cells (ECs), and fibroblasts was detected via reverse transcription-quantitative PCR analysis (n = 3); D: Relative expression of miR-29b-3p in ECs transfected with miR-29b-3p mimics, miR-29b-3p inhibitors and their corresponding negative controls (miR-NC and inhibit-NC, respectively); E-H: Protein expression of GPX4 and xCT were detected in ECs after indicated treatment (n = 3); I: Relative expression of malondialdehyde in the hearts from indicated groups were determined by the commercial kit (n = 6); J: The content of Fe²⁺ in ECs was assessed by the commercial kit (n = 6). ^aP < 0.05 vs NC; ^bP < 0.05 vs HG/FFA. FA: Farrerol; DCM: Diabetic cardiomyopathy; HG/FFA: High glucose and free fatty acid.